Is amphiphysin IgG linked to paraneoplastic neurologic syndromes without proving active cancer?

Amphiphysin IgG is a high-risk onconeural antibody that meaningfully raises concern for a paraneoplastic neurologic syndrome (PNS), but it is not a stand-alone diagnosis of either PNS or active malignancy.

Clinical association and cancer relevance

• In a clinically characterized seropositive cohort, cancer was identified in 50/63 patients (79.4%), including 46 histologically confirmed tumors. Small-cell lung cancer (SCLC) and breast carcinoma predominated (reported lung 61%, breast 35%).
• Associated neurologic presentations are heterogeneous: stiff-person phenomena, neuropathy/sensory neuronopathy, encephalopathy or limbic encephalitis, myelopathy/encephalomyelitis, cerebellar ataxia, and polyradiculoneuropathy. Stiff-person syndrome is important but is not the sole amphiphysin-associated phenotype.
• Amphiphysin is classified as a high-risk antibody in PNS-Care criteria, indicating a >70% cancer association at the population level.

Interpretation and testing considerations

• A positive result does not prove that cancer is currently present, recurrent, or active. Active malignancy requires independent clinical, imaging, or pathologic confirmation.
• Isolated serum-only, immunoblot, or line-blot positivity—particularly at low titer or with an atypical neurologic syndrome—may be false positive. Confirmation with tissue-based immunohistochemistry/immunofluorescence or another validated assay is important; serum and CSF testing can help establish neurologic relevance.

Tumor evaluation

• Confirmed amphiphysin IgG warrants prompt, phenotype- and antibody-directed screening, especially for SCLC and breast cancer.
• If the initial evaluation is negative but the phenotype is compatible and risk remains high, consensus guidance supports repeat screening every 4–6 months for two years, tailored to clinical course and risk factors.

Bottom line

• Amphiphysin IgG is a strong paraneoplastic risk signal, particularly for SCLC and breast cancer, but it must be interpreted with validated testing, the neurologic phenotype, and current—and sometimes serial—tumor evaluation rather than as proof of active cancer.